About Us

Cellmid is an Australian Life Sciences accelerator with lead programs in multiple disease indications 

The Company, through its wholly owned subsidiaries Lyramid, Kinera, and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally.

Through its Advangen business, Cellmid sells its FGF5 inhibitor hair growth products in Australia and Japan, and is expanding distribution in other territories.  For further information, please see